#62
Notable Clinical Interest
Emerging findings or policy developments worth monitoring closely.
Clinicians need to understand this evidence linking adolescent cannabis use to psychotic disorders when counseling patients and families about risks, particularly given ongoing debates about cannabis rescheduling that may increase accessibility. The doubling of psychotic disorder risk in a large cohort provides concrete data to inform informed consent discussions and preventive conversations with high-risk populations, especially pregnant patients and adolescents. As federal policy evolves, clinicians should anticipate increased patient questions about cannabis safety and be prepared to reference current epidemiological evidence rather than relying on outdated assumptions.
A recent large cohort study following 463,000 adolescents found that cannabis use was associated with more than double the risk of developing psychotic disorders, evidence that has been presented in federal court proceedings concerning potential rescheduling of marijuana. This finding carries significant clinical implications for adolescent psychiatry and primary care, as it suggests that cannabis use during critical neurodevelopmental periods may substantially increase vulnerability to psychotic illness, particularly in genetically predisposed individuals. The study’s scale and longitudinal design provide robust epidemiological support for the documented association between cannabis and psychosis risk, strengthening the evidence base that clinicians should use when counseling young patients and their families about cannabis exposure. These data become particularly relevant in the context of federal drug policy changes, as rescheduling could increase accessibility and perceived safety, potentially leading to greater adolescent use without corresponding clinical awareness of psychotic risks. Clinicians should remain vigilant about obtaining detailed cannabis use histories from adolescent and young adult patients presenting with early psychotic symptoms and counsel families that adolescent brains may be uniquely vulnerable to cannabis-related psychiatric complications.
“This 2025 cohort study of nearly half a million adolescents reporting double the psychotic disorder risk in cannabis users is significant observational data we cannot ignore, though we need to be careful about causation versus correlation and individual vulnerability factors. The signal is strong enough that it reinforces what we already counsel patients and families about: adolescent brain development and cannabis use carry real risks that should weigh heavily in any policy or personal decision-making.”
🧠 While large observational studies documenting associations between adolescent cannabis use and psychotic disorders contribute important epidemiological data, clinicians should interpret these findings within their methodological context, recognizing that cohort studies cannot definitively establish causation and may be confounded by unmeasured factors such as underlying genetic vulnerability, concurrent substance use, or socioeconomic stressors that predispose both to cannabis initiation and psychotic illness. The doubling of risk reported in studies of this scale represents a concerning signal that warrants clinical attention, particularly given the developing adolescent brain’s known vulnerability to cannabis-related neurotoxic effects, yet individual risk remains probabilistic rather than deterministic, and rescheduling decisions involve complex policy trade-offs beyond the scope of any single study. For practicing clinicians, this evidence supports counseling adolescent and young adult patients—especially those with personal or family history of psychosis—about cannabis risks as part
💬 Join the Conversation
Have a question about how this applies to your situation?
Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers?
Join the forum discussion →
Have thoughts on this? Share it:
